Marquet Magda 4

What Happened

• Magda Marquet, a director of First Tracks Biotherapeutics, received 6,030 shares on June 15, 2026 through the exercise/conversion of a derivative security (Code M). The acquisition price shown is $0.00 — these shares were settled from previously granted restricted stock units (RSUs) and no cash was paid at settlement.

Key Details

• Transaction date: June 15, 2026; Form 4 filed: June 17, 2026 (appears timely).
• Shares acquired: 6,030 shares; exercise/conversion price: $0.00 (no cash paid).
• Filing shows a corresponding conversion/disposition entry for the derivative instrument (standard when RSUs convert to common stock).
• Footnotes: F1 — each RSU converts to one share for no consideration; F2 — 100% of the RSUs vested on June 15, 2026 subject to continued service.
• Shares owned after the transaction are not specified in the excerpt provided.

Context

• This was not an open‑market purchase or a sale but the settlement of RSUs upon vesting; such transactions reflect compensation/vesting rather than a market bet by the insider. Code M indicates conversion/exercise of a derivative (here, RSUs converting into common stock).